

ABSORPTION	(1)	preganglionic nerve	
absorption kinetics	8682	stimulation	8673
body fluid exposure	8682	rat brain extracts	8696
diffusion layer pH	8682	reserpine pretreatment	8671
dissociation constants	8682	serotonin pretreatment	8715
drug solubility	8682	spinal cats	8671
experimentally observed rates	8682	sympathetic ganglia	8672
implant surface area	8682	8673	
physicochemical properties	8682	TM-10 pretreatment	8671
serum solubility	8682	tone effects	8715
subcutaneous pellet		"total" acetylcholine	
implantation	8682	activity	8696
theoretically calculated		vasoconstrictor activity	8715
rates	8682	vasodilator activity	8715
ACETAZOLAMIDE	(2)	ACETYLSTROPHANTHIDIN	(4)
chlorophthalidolone comparison	8720	frequency-force relationship	8685
electrolyte excretion	8720	isolated heart muscle	8685
intact animals	8720	post-stimulation potentiation	8685
ACETYLCHOLINE	(3)	ADRENAL GLANDS	(5)
aortic chains	8715	epinephrine concentration	8706
atropine	8715	morphine-tolerant animals	8706
8671		nalorphine pretreatment	8706
brain betaine esters	8696	nalorphine-induced withdrawal	8706
brain choline esters	8696	norepinephrine concentration	8706
chronic denervation	8672	l-phenyl-2-hydrazinopropane	
cocaine modification	8671	(JB 516)	8706
concentration effect	8715	rectal temperature	8706
contraction response	8671	ADRENALECTOMY	(6)
dose effect	8671	2,2'-bipyridine hyperglycemia	8711
dose-response curves	8671	blocking effect	8711
8715		fasted rats	8711
epinephrine pretreatment	8715	ADRENERGIC RECEPTOR MECHANISM	(7)
ether narcosis	8696	bronchiolar smooth muscle	8692
frog rectus preparation	8696	bronchomotor responses	8692
intra-arterial injection	8671	dichloroisoproterenol	8692
8672		pulmonary vasomotor responses	8692
isolated rabbit aorta	8715	sympathomimetic	
methacholine	8715	bronchodilators	8692
muscarinic action	8671	ADRENOCORTICAL STEROIDS	(8)
nicotinic action	8671	aldosterone	8675
nictitating membrane	8671	cardiotonic action	8675
norepinephrine modification	8671	isolated heart muscle	8675
norepinephrine pretreatment	8715	ALCOHOL INTOXICATION,	
pentobarbital narcosis	8696	EXPERIMENTAL	(9)
phase responses	8715	albino mice	8699
phenoxybenzamine modification	8671	chloroform-induced	
postganglionic action		liver damage	8699
potentials	8673	ALDOSTERONE	(10)
postganglionic responses	8672	cardiotonic action	8675
potentiating action	8673	direct myocardial effect	8675

SUBJECT INDEX

ALD-BAR

VOL. 135

isolated heart muscle	8675	AORTA, ISOLATED	(21)
pH values	8675	acetylcholine constrictor	
<u>Gamma</u> -AMINOBTYRIC ACID	(11)	effect	8715
brain content	8707	acetylcholine dilator effect	8715
morphine tolerant animals	8707	rabbit aortic chains	8715
nalorphine-induced abstinence	8707	ARTERIES, PULMONARY	(22)
AMPHETAMINE	(12)	anesthetized dogs	8687
motor activity response	8669	bretylum pretreatment	8687
tetrahydrocannabinols	8669	cardiac response	8687
<u>d</u> -AMPHETAMINE	(13)	dichloroisoproterenol	
aggregated animals	8698	pretreatment	8687
albino mice	8698	DMPP response	8687
drug antagonists	8698	epinephrine pretreatment	8687
excitatory effects	8698	heart rate	8687
isolated animals	8698	heart-lung preparation	8687
lethal effects	8698	left ventricular force	8687
strain difference	8698	partial occlusion	8687
variable responses	8698	right ventricular pressure	8687
ANALGESICS	(14)	sympathetic cardiac reflexes	8687
cellular adaptation	8678	systemic blood pressure	8687
morphinized rats	8678	systemic flow	8687
narcotic agents	8678	ATROPINE	(23)
ANESTHETICS, GENERAL	(15)	ACh responses	8672
brain esters	8696	blocking action	8714
ether narcosis	8696	DFF-induced discharge	8672
pentobarbital narcosis	8696	ganglionic stimulants	8714
"total" acetylcholine		postganglionic potentials	8672
activity	8696	sympathetic ganglia	8672
ANTACIDS	(16)	AUTONOMIC GANGLIA	(24)
polymyxin B-induced		anesthetized cat	8714
gastric hemorrhage	8702	blocking agents	8714
protective activity	8702	DMPP stimulant action	8714
ANTICHOLINERGIC AGENTS	(17)	5-HT stimulant action	8714
polymyxin B-induced		inferior mesenteric ganglion	8714
gastric hemorrhage	8702	AUTONOMIC NERVOUS SYSTEM	(25)
protective activity	8702	acetylcholine effect	8691
ANTIDIURESIS	(18)	blood pressure	8691
benzothiadiazines	8720	heart phosphorylase a	
diabetes insipidus	8720	activity	8691
ANTIHISTAMINES	(19)	isolated heart	8691
polymyxin B-induced		parasympathetic stimulation	8691
gastric hemorrhage	8702	sympathetic ganglionic	
protective effect	8702	stimulation	8691
ANTIHYPERTENSIVE AGENTS	(20)		
experimental atheromatosis	8718	BARBITAL	(26)
hypertensive rats	8718	acute toxicity	8694
hypcholesterolemic activity	8718	blood levels	8694
mecamylamine	8718	diffusion rate	8694
normotensive rats	8718	distribution volume	8694
reserpine	8718		

SUBJECT INDEX

1962

BAR-BLO

environmental temperature	8694	toxicity	8711
male rats	8694	BLADDER	(34)
mortality rate	8694	atropine	8674
oil-water distribution	8694	carbachol	8674
plasma protein binding	8694	contraction response	8674
rectal temperature	8694	hexamethonium	8674
BARBITURATES	(27)	intravesical pressure	8674
albino rats	8667	pelvic nerve preparation	8674
brain 5-HT content	8667	tetraethylammonium	8674
BENZOTHIADIAZINES	(28)	tremorine effect	8674
action duration	8720	BLOOD	(35)
antidiuretic potency	8720	anesthetized rabbits	8703
benzhydroflumethiazide	8720	arginine esterase activity	8701
chlorothiazide	8720	CSF-blood transport	8703
cyclopenthiiazide	8720	esterolytic activity	8701
diabetes insipidus	8720	heparin effect	8701
dose-response curves	8720	human subjects	8701
hydrochlorothiazide	8720	lipid-insoluble substances	8703
trichlormethiazide	8720	BLOOD PRESSURE	(36)
BENZOYL-1-ARGININE ETHYL ESTER		acetylcholine	8677
(BAEE)	(29)	acetylcholine response	8686
heparinized plasma hydrolysis	8701	anesthetized cats	8713
human subjects	8701	anesthetized chickens	8686
oxalated plasma hydrolysis	8701	anesthetized dogs	8668
serum hydrolysis	8701	8676 8689 8697 8716	
BENZYLHYDRAZINE	(30)	anesthetized rabbits	8689
MAO inhibitor activity	8664	anesthetized rats	8677
NQS effect	8664	antihypertensive agents	8718
preincubation period	8664	atropine	8677
BENZYLOROXYGRAMINE	(31)	atropine effect	8674
blocking action	8714	8676	
ganglionic stimulants	8714	basilar artery ligation	8689
BIOASSAY	(32)	carotid body chemoreceptors	8697
brain 5-HT content	8667	carotid sinus baroreceptors	8697
CNS depressants	8667	carotid sinus denervation	8676
heart	8665	C6-C14 tissue concentration	8713
indoleacetic acid formation	8665	C-O pressor reflex	8674
monoamine oxidase activity		C-O pressor response	8668
<u>in vitro</u>	8665	compound 48/80	8686
sympathetic ganglia	8665	cyclopropane effects	8697
tissue homogenates	8665	cyclopropane responses	8716
tryptamine conversion	8665	depressor activity	8674
venus mercenaria heart	8667	dichloroisoproterenol	
2,2'-BIPYRIDINE	(33)	pretreatment	8669
blood glucose responses	8711	epinephrine pressor response	8669
chelating agent	8711	8677	
dose-response relationships	8711	experimental atheromatosis	8718
fasted rats	8711	experimental hypertension	8718
fed rats	8711	guanethidine effect	8668
hyperglycemic activity	8711	hexamethonium blockade	8676
time-response relationships	8711	hexamethonium effect	8674

SUBJECT INDEX

BLO-BRA

VOL. 135

hexamethonium pretreatment	8669	ataxia	8704
hexamethonium-C ¹⁴	8713	behavioral effects	8705
histamine response	8686	betaine ester concentration	8696
hydroquinone responses	8689	cellular adaptation	8678
intracarotid injection	8689	cerebral cortical slices	8678
intravenous injections	8677	8700	
intravertebral injection	8689	chloral hydrate concentration	8704
isoproterenol depressor		choline ester concentration	8696
response	8669	CNS depressants	8667
lobeline	8677	cross-cellular adaptation	8700
male rats	8718	H ³ -DCI localization	8693
midbrain section	8669	depression stages	8704
nicotine	8677	electrical activity	8705
nicotine-like actions	8676	epinephrine uptake	8666
norepinephrine pressor		ether narcosis	8696
response	8669	evoked seizure activity	8705
8677		hexamethonium-C ¹⁴	
norepinephrine response	8668	concentration	8713
parabromdylamine effect	8686	hippocampus	8705
phenoxybenzamine pretreatment	8676	<u>gamma</u> -hydroxybutyrate	8705
8677		5-hydroxytryptamine content	8667
pressor effects	8716	8707	
pressor responses	8676	intercolumnar tubercle	8666
resorcinol responses	8689	KCl-stimulated slices	8700
retama	8676	mepheridine	8700
serotonin response	8686	methadone	8700
serum cholesterol levels	8718	morphine tolerant animals	8706
spinal cord transection	8689	8707	
spinal section	8669	morphinized rats	8678
tissue histamine depletion	8686	8700	
tremorine	8674	nalorphine reversal	8678
tryptamine response	8686	nalorphine-induced abstinence	8706
tyramine response	8668	8707	
vagotomy	8674	norepinephrine concentration	8706
8676		oxygen consumption	8700
vagus nerve stimulation	8674	pentobarbital narcosis	8696
BLOOD SUGAR	(37)	pharmacological responses	8713
2,2'-bipyridine hyperglycemia	8711	1-phenyl-2-hydrazinopropane	
fasted rats	8711	(JB-516)	8706
BODY TEMPERATURE	(38)	pineal body	8666
morphine-tolerant dogs	8706	rat brain extracts	8696
nalorphine administration	8706	rectal temperature	8706
BRAIN	(39)	reserpine effect	8666
albino mice	8704	righting reflex	8704
albino rats	8667	special areas	8666
<u>gamma</u> -aminobutyric acid		species differences	8706
content	8707	tissue homogenates	8704
amygdala	8705	"total" acetylcholine	
anesthetized cats	8666	activity	8696
anesthetized dogs	8693	trichloroethanol	
area postrema	8666	concentration	8704

SUBJECT INDEX

1962

BRE-CEN

BRETYLIUM TOSYLATE	(40)	intraluminal pressure	8697
action mechanism	8687	nerve action potentials	8697
DMPP responses	8687	peak frequency discharge	8697
heart-lung preparation	8687	pressure-frequency discharge	
pulmonary arterial occlusion	8687	curves	8697
BROM-LYSERGIC ACID DIETHYLAMIDE		pulsatile stimulation	8697
blocking action	(41) 8714	receptor pressure threshold	8697
ganglionic stimulants	8714	vagosympathetic nerve block	8697
BUTYNAMINE	(42)	CATECHOLAMINES	(48)
butyramine-C ¹⁴ administration	8683	adrenal gland content	8706
<u>N</u> -demethylation <u>in vitro</u>	8683	anesthesia levels	8716
des- <u>N</u> -methyl butyramine		brain content	8706
formation	8683	chronotropic effects	8717
enzyme activity	8683	cyclopropane inhalation	8716
human subjects	8683	endogenous release	8717
metabolism <u>in vivo</u>	8683	heart content	8708
radioactive metabolites	8683	heart-muscle	8717
		inotropic effects	8717
		intestine content	8708
		morphine tolerance	8706
CARBONIC ANHYDRASE INHIBITION		morphine-tolerant animals	8708
brain 5-HT content	(43) 8667	nictitating membrane content	8690
methazolamide	8667	norepinephrine sensitization	8690
CARDIOACTIVE GLYCOSIDES	(44)	<u>N</u> -oxide analogs	8717
concentration effect	8685	plasma concentration	8716
frequency-force relationship	8685	pyridine derivatives	8717
positive inotropic effect	8685	spleen content	8708
post-stimulation potentiation	8685		
CARDIOVASCULAR SYSTEM	(45)	CELLS, CEREBRAL CORTEX	(49)
anesthetized dogs	8716	cerebral cortical slices	8678
autonomic nervous system	8691	8700	
blood pressure	8691	cross-cellular adaptation	8700
cyclopropane responses	8716	KCl-stimulated slices	8700
heart contractile force	8691	meperidine	8700
heart phosphorylase a		methadone	8700
activity	8691	morphine adaptation	8678
isolated heart	8691	morphinized rats	8700
resorcinol isomers	8689	nalorphine effect	8700
spinal cord action site	8689	nalorphine reversing effect	8678
sympathetic stimulation	8689	oxygen consumption	8700
CAROTID BODY	(46)	CENTRAL NERVOUS SYSTEM	(50)
anesthetized dogs	8697	adrenal medullary hormones	8711
chemoreceptor sensitivity	8697	albino mice	8705
cyclopropane inhalation	8697	albino rats	8667
CAROTID SINUS	(47)	analgesics	8667
acute hemorrhage	8697	anesthetics	8667
anesthetized dogs	8697	anesthetized cats	8666
arterial blood pressure	8697	anticonvulsants	8667
baroreceptor sensitivity	8697	behavioral studies	8705
constant pressure distensions	8697	bioassay	8667
cyclopropane inhalation	8697	2,2'-bipyridine-induced	
electrocardiogram	8697	hyperglycemia	8711

SUBJECT INDEX

GEN-CHO

VOL. 135

blood-brain barrier	8666	chloroform-ethanol	
brain	8666	pretreatment	8699
brain 5-HT levels	8667	hepatotoxic susceptibility	8699
carbonic anhydrase inhibitors	8667	liver content	8699
catatonia	8669	liver damage	8699
catecholamine content	8666	liver lipids	8699
cerebellum	8666	p-CHLOROMERCURIBENZOATE (p-CMB)	
depressant drugs	8667	acid-base balance	(55) 8680
depressant effects	8705	chlorothiazide activity	8680
EEG	8705	electrolyte excretion	8681
epinephrine infusion	8666	inhibitor activity	8680
epinephrine uptake	8666	mercurial diuresis	8681
guanethidine inhibitor effect	8668	mercurial diuresis	8680
hexobarbital sleeping time	8705	renal blood flow	8681
<u>gamma</u> -hydroxybutyrate	8705	renal hemodynamic changes	8681
hypnotics	8667	renal perfusion pressure	8681
hypothalamus	8666	saline diuresis	8680
MAO inhibitors	8667	urine flow	8681
pentobarbital sleeping time	8705	water excretion	8681
reflex activity	8705	p-CHLOROMERCURIPHENYL SULFONATE	
reflexes	8669	inhibitor activity	(56) 8680
reserpine pretreatment	8666	mercurial diuresis	8680
sedatives	8667	CHLOROTHIAZIDE	(57)
spontaneous motor activity	8705	antidiuretic effect	8720
tetrahydrocannabinols	8669	diabetes insipidus	8720
tissue concentration	8666	probenecid influence	8720
vasomotor activity	8668	CHLORPHENIRAMINE	(58)
CEREBROSPINAL FLUID	(51)	polymyxin B-induced	
anesthetized rabbits	8703	gastric hemorrhage	8702
C ¹⁴ -labeled saccharides	8703	protective effect	8702
CSF-blood transport	8703	CHLORPHTHALIDOLONE	(59)
intracisternal injection	8703	action duration	8720
intraventricular injection	8703	antidiuretic potency	8720
lipid-insoluble substances	8703	diabetes insipidus	8720
radioactivity measurements	8703	electrolyte excretion	8720
urinary excretion	8703	CHLORPROMAZINE	(60)
CHELATING AGENTS	(52)	polymyxin B-induced	
2,2'-bipyridine	8711	gastric hemorrhage	8702
fasted rats	8711	protective effect	8702
hyperglycemic response	8711	CHOLESTEROL	(61)
CHLORAL HYDRATE	(53)	antihypertensive agents	8718
albino mice	8704	atherogenic diet	8718
brain 5-HT content	8667	fecal excretion	8718
brain tissue concentration	8704	hypertensive rats	8718
hypnotic activity	8704	serum levels	8718
metabolism	8704	CHOLINESTERASES	(62)
trichloroethanol comparison	8704	bovine erythrocytes	8674
CHLOROFORM	(54)	intestinal mucosa	8674
acute ethanol intoxication	8699	neostigmine comparison	8674
chloroform pretreatment	8699	tremorine inhibitor activity	8674

SUBJECT INDEX

1962

COC-DIM

COCAINE	(63)	benzothiadiazines	8720
acetylcholine response	8671	hydrochlorothiazide	8720
blocking action	8714	hypothalamic electrolytic	
contraction response	8671	lesions	8720
ganglion stimulants	8714	male rats	8720
intravenous administration	8671	water intake	8720
nictitating membrane	8671	DIBENZYLIN	(72)
reserpine pretreatment	8671	blocking action	8714
CONTRACTION, HEART	(64)	ganglionic stimulants	8714
isolated heart muscle	8685	polymyxin B-induced	
ouabain effect	8685	gastric hemorrhage	8702
post-stimulation potentiation	8685	protective effect	8702
rate-dependent mechanism	8685	DICHLOROISOPROTERENOL	(73)
CORONARY BLOOD FLOW	(65)	reversing action	8692
isolated perfused rat heart	8677	sympathomimetic	
posterior pituitary hormone	8677	bronchodilators	8692
COTININE	(66)	H^3 -DICHLOROISOPROTERENOL	(74)
chloroform-soluble		albino mice	8693
metabolites	8709	anesthetized dogs	8693
human subject	8709	lipoid solubility	8693
metabolism	8709	metabolism	8693
oral administration	8709	physiological disposition	8693
urinary excretion	8709	plasma concentration	8693
CYCLOPROPANE	(67)	tissue binding	8693
action mechanism	8697	tissue distribution	8693
anesthesia levels	8716	DIGITALIS GLYCOSIDES	(75)
anesthetized dogs	8697	frequency-force relationship	8685
8716		isolated heart muscle	8685
carotid body chemoreceptors	8697	post-stimulation potentiation	8685
carotid sinus baroreceptors	8697	DIHYDROERGOTAMINE	(76)
circulatory responses	8716	adrenergic blockade	8711
corneal reflex	8716	2,2'-bipyridine hyperglycemia	8711
lid reflex	8716	fasted rats	8711
sympathoadrenal responses	8716	DIISOPROPYL FLUOROPHOSPHATE	(77)
CYPROHEPTADINE	(68)	acetylcholine effect	8672
polymyxin B-induced		ganglionic blocking agents	8672
gastric hemorrhage	8702	intra-arterial injections	8672
protective effect	8702	postganglionic action	
		potentials	8672
		postganglionic discharge	8672
		repetitive preganglionic	
		stimulation	8672
		sympathetic ganglia	8672
<u>N</u> -DEMETHYLATION	(69)	DIMETHYL-HEPTYL-PYRAN (DMHP)	(78)
butylamine	8683	chemical structure	8669
rat liver microsomes	8683	pharmacological effects	8669
substrate concentration	8683	1,1-DIMETHYL-4-PHENYL-	
DEXTRAN	(70)	PIPERAZINIUM (DMPP)	(79)
CSF-blood transport	8703	action site	8687
nephrectomized animals	8703	anesthetized cat	8714
DIABETES INSIPIDUS,		atropine pretreatment	8687
EXPERIMENTAL	(71)		
acetazolamide	8720		
antidiuretic effect	8720		

SUBJECT INDEX

DIM-ENZ

VOL. 135

biphasic response	8687	morphine	8682
bretylium pretreatment	8687	neutral compounds	8682
ganglionic blocking agents	8714	organic weak acids	8682
ganglionic stimulation	8687	organic weak bases	8682
8714		physicochemical properties	8682
heart rate	8687	subcutaneous pellet	
heart-lung preparation	8687	implantation	8682
inferior mesenteric ganglion	8714	sulfonamides	8682
left ventricular force	8687	tetracycline	8682
right ventricular pressure	8687	theobromine	8682
systemic blood flow	8687	theophylline	8682
systemic blood pressure	8687	tolbutamide	8682
DIPHENYLHYDANTOIN (80)		urea	8682
brain 5-HT content	8667		
1,4-DIPYRROLIDINO-2-BUTYNE (TREMORINE) (81)		ELECTROCARDIOGRAM (86)	
action sites	8674	anesthesia levels	8716
autonomic effects	8674	anesthetized rats	8677
DIURESIS, MERCURIAL (82)		cyclopropane inhalation	8716
ammonium chloride		posterior pituitary hormone	8677
pretreatment	8680	ELECTROENCEPHALOGRAM (87)	
anesthetized dogs	8680	arousal response	8705
chloride excretion	8680	ascending reticular system	8705
chlormerodrin response	8680	cortical areas	8705
p-chloromercuriphenyl		evoked seizures	8705
sulfonate	8680	γ -hydroxybutyrate	8705
p-CMB inhibitor activity	8680	spindling	8705
dibenamine	8680	thalamo-cortical recruitment	8705
dimercaprol reversal	8680	ELECTROLYTES (88)	
dose-response relationship	8680	acetazolamide	8720
glomerular filtration	8680	chlorophthalidolone	8720
mercaptomerin response	8680	hydrochlorothiazide	8720
mersalyl response	8680	urinary excretion	8720
nondiuretic mercurial effects	8680	ENZYMES (89)	
oxophenarsine	8680	albino mice	8699
SY-28	8680	autonomic nervous system	8691
urine flow	8680	blood arginine esterase	
DIURESIS, WATER (83)		activity	8701
human subjects	8677	butynamine N-demethylation	8683
lobeline inhibitor activity	8677	chloroform-induced	
urine volume	8677	liver damage	8699
DIURETICS, MERCURIAL (84)		demethylase activity	8683
electrolyte excretion	8681	ethanol pretreatment	8699
perfused kidney	8681	glycolytic systems	8679
water excretion	8681	heart phosphorylase a	
DRUGS, ADMINISTRATION (85)		activity	8691
absorption rate	8682	heparin effect	8701
barbiturates	8682	human subjects	8701
cholesterol	8682	isolated heart	8691
codeine	8682	liver fluke homogenates	8679
medrol	8682	liver succinic dehydrogenase	
		activity	8699

SUBJECT INDEX

1962

ENZ-GAN

MAO activity	8665	"total" acetylcholine	
phosphofructokinase activity	8679	activity	8696
rat liver microsomes	8683	ETHER, DIETHYL	(95)
sensitivity assay	8665	brain 5-HT content	8667
serotonin effect	8679	inhalation anesthesia	8667
tissue homogenates	8665	ETHYL MERCURY CHLORIDE	(96)
EPHEDRINE	(90)	mercurial diuresis	8680
action mechanism	8670	nondiuretic mercurial	8680
inhibitor activity	8670	N-ETHYL-NORTROPINE-BENZHYDRYL-	
isolated rabbit ileum	8670	ETHER	(97)
reserpine pretreatment	8670	antiarrhythmia action	8684
EPINEPHRINE	(91)	isolated cat heart	8684
acetylcholine response	8715	isolated heart muscle	8684
bronchomotor responses	8692	pentylentetrazol	8684
DCI pretreatment	8692		
dose-response curves	8670		
inhibitor activity	8670	FASCIOLA HEPATICA	(98)
isolated aorta	8715	glycolysis	8679
isolated rabbit ileum	8670	liver fluke homogenates	8679
perfusion pressure	8692	serotonin effect	8679
polymyxin B-induced			
gastric hemorrhage	8702	GANGLIONIC BLOCKING AGENTS	(99)
protective effect	8702	acetylcholine responses	8672
pulmonary arterial pressure	8692	<u>gamma</u> -aminobutyric acid	8673
reserpine pretreatment	8670	anesthetized cat	8714
ventilation overflow	8692	atropine	8673
H ³ -EPINEPHRINE	(92)	8714	
blood-brain barrier	8666	benzyloxygramine	8714
CNS uptake	8666	brom-lysergic acid	
intravenous infusion	8666	diethylamide	8714
isolated brain tissue	8666	cell group responses	8673
labeled amine incubation		cocaine	8714
<u>in vitro</u>	8666	DFP-induced postganglionic	
pituitary slices	8666	discharge	8672
reserpine pretreatment	8666	dibenzylamine	8714
tissue slices	8666	differential blockade	8673
ETHANOL	(93)	DMPP-induced stimulation	8714
acute intoxication	8699	epinephrine	8673
albino mice	8699	ganglionic transmission	8672
blood content	8699	hexamethonium	8673
chloroform-induced		8714	
liver damage	8699	hexamethonium-Cl ₄	8713
hepatotoxic susceptibility	8699	5-HT-induced stimulation	8714
liver content	8699	inferior mesenteric ganglion	8714
liver lipids	8699	intra-arterial injections	8672
oral administration	8699	lysergic acid diethylamide	8714
physiological response	8699	morphine	8714
ETHER	(94)	pharmacological activity	8713
anesthetized rats	8696	postganglionic action	
brain esters	8696	potentials	8672

SUBJECT INDEX

GAN-HEA

VOL. 135

preganglionic nerve stimulation	8672	HEART	(105)
presynaptic nerve terminals	8672	"aging" effect	8712
sympathetic ganglia	8672	anesthetized intact dogs	8689
8673		atropine pretreatment	8717
synaptic depressants	8673	bioassay	8665
tetraethylammonium	8673	blood pressure	8689
tissue distribution	8713	cardiac glycosides	8712
d-tubocurarine	8673	cardiac output	8717
GANGLIONIC STIMULANTS	(100)	catecholamine content	8708
acetylcholine effect	8673	8717	
anesthetized cat	8714	competence index	8717
blocking agents	8714	contractile force	8689
cell group responses	8673	8712	
DMPP activity	8687	digitoxin	8712
8714		<u>N,N</u> -dimethylformamide muscle	
heart-lung preparation	8687	extracts	8712
5-hydroxytryptamine activity	8714	drug effects	8712
inferior mesenteric ganglion	8714	epinephrine	8712
nicotine	8673	epinephrine/norepinephrine	
sympathetic ganglia	8673	ratio	8708
tetramethylammonium	8673	heart-lung preparation	8717
GASTRIC HEMORRHAGE	(101)	inotropic effects	8717
gastric ulcer formation	8702	intravertebral injection	8689
hemostasis	8702	MAO activity	8665
mortality	8702	methacholine	8712
polymyxin B induced	8702	morphine-induced convulsions	8708
protective agents	8702	morphine-tolerant animals	8708
GLYCOLYSIS	(102)	nerve stimulation	8712
liver fluke homogenates	8679	nucleic acid fragments	8712
serotonin-treated flukes	8679	open-chest dogs	8689
GUANETHIDINE	(103)	8712	
anesthetized dogs	8668	ouabain	8712
blood pressure	8668	<u>N</u> -oxide analogs	8717
blood-brain barrier	8668	pentobarbital failure	8717
bradycardia	8668	perfusion experiments	8712
cardiac norepinephrine		potassium	8712
content	8688	pyridine derivatives	8717
cardioaccelerator effect	8688	rate effect	8712
central administration	8668	8717	
central inhibition	8668	resorcinol responses	8689
heart rate	8688	right atrial pressure	8717
intact rat heart	8688	spinal cord transection	8689
intravenous administration	8668	tissue homogenates	8665
isolated mammalian heart	8688	veratridine	8712
reserpine comparison	8688	HEART ARRHYTHMIA	(106)
vasodepressor effect	8668	A-V block	8684
vasomotor activity	8668	parasympathetic blockade	8684
HARMALINE	(104)	pentylene tetrazol	8684
brain 5-HT content	8667	premature ventricular	
		contractions	8684
		sinus bradycardia	8684

sinus tachycardia	8684	pentylentetrazol effect	8684
ventricular fibrillation	8684	perfused rabbit heart	8676
ventricular tachycardia	8684	perfused rat heart	8677
HEART AURICLES (107)		phosphorylase a activity	8691
atropine pretreatment	8717	physostigmine	8691
chronotropic effects	8717	posterior pituitary hormone	8677
DCI pretreatment	8717	pulmonary arterial pressure	8688
epinephrine	8717	rabbit heart	8674
inotropic effects	8717	reserpine pretreatment	8688
isolated cat auricles	8717	retama	8676
nicotine pretreatment	8717	right atrial pressure	8688
<u>N</u> -oxide analogs	8717	S-A pacemaker sensitivity	8688
pyridine derivatives	8717	systemic output	8688
reserpine pretreatment	8717	tremorine	8674
SKF-6890A pretreatment	8717	vagal stimulation	8691
HEART, ISOLATED (108)		veratramine	8688
acetylcholine	8691	work capacity	8688
acute hemorrhage	8691	HEART MUSCLE, ISOLATED (109)	
adrenalectomy	8691	aldosterone	8675
aldosterone	8675	cardiac arrhythmias	8684
arterial pressure	8688	cardioactive glycosides	8685
atropine	8691	cat atrium	8685
autonomic nervous system	8691	cat papillary muscles	8675
bretylum	8691	8684	
cardiac arrhythmias	8684	contraction amplitude	8684
carotid blood pressure	8691	contraction force	8675
cat hearts	8675	dose-response curves	8684
competence tests	8688	electrograms	8684
contraction amplitude	8675	frequency-force relationship	8685
coronary flow	8675	guinea-pig ventricle	8685
coronary perfusion	8684	heart rate	8684
dichloroisoproterenol	8691	inotropic effects	8675
DMPP	8691	isolated cat auricles	8684
dose-response curves	8688	isolated cat heart	8684
<u>N</u> -ethyl-nortropine-		myograms	8684
benzhydryl-ether	8684	ouabain	8675
guanethidine	8688	parasympathetic blocking	
heart rate	8688	agents	8684
8691		pentylentetrazol	8684
heart-lung preparation	8688	pH values	8675
inotropic effects	8674	post-stimulation potentiation	8685
isolated cat heart	8684	rabbit atrium	8685
isometric systolic tension	8691	rabbit ventricle	8685
left atrial pressure	8688	SC-8109	8675
McNeil-A-343	8691	tetrahydrocortisol	8675
negative chronotropic effect	8674	Tyrode-solution incubation	8685
norepinephrine	8688	ventricular threshold	8684
norepinephrine content	8688	HEART RATE (110)	
norepinephrine response	8688	atropine effect	8674
open-chest rat preparation	8691	bradycardia	8674
pentobarbital-induced failure	8675	C6-C ¹⁴ tissue concentration	8713

SUBJECT INDEX

HEA-HYD

VOL. 135

cyclopropane effects	8716	HEXOBARBITAL HYPNOSIS	(115)
dose-response curves	8688	DMHP effect	8669
guanethidine	8688	<u>gamma</u> -hydroxybutyrate	8705
hexamethonium effect	8674	MOP effect	8669
hexamethonium-C ¹⁴	8713	sleeping time	8669
isolated dog heart	8688	8705	
norepinephrine response	8688	HISTAMINE	(116)
reserpine	8688	anesthetized chickens	8686
tachycardia	8716	bioassays	8686
tetraethylammonium	8674	compound 48/80 injection	8686
tremorine	8674	hemorrhagic lesions	8702
vagus nerve stimulation	8674	histamine injection	8686
8713		oxytocin injection	8686
HEMOSTASIS	(111)	rat stomach	8702
albino rats	8702	serotonin injection	8686
polymyxin B-induced		tryptamine injection	8686
gastric hemorrhage	8702	urinary excretion	8686
HEPARIN	(112)	HISTAMINE LIBERATION	(117)
blood arginine esterase		albino rats	8702
activity	8701	anesthetized chickens	8686
human subjects	8701	gastric ulcer formation	8702
HEXAMETHONIUM	(113)	polymyxin B-induced	
ACh responses	8672	gastric hemorrhage	8702
blocking action	8714	serotonin-induced	
DFP-induced postganglionic		vasodepression	8686
discharge	8672	tryptamine-induced	
differential ganglionic		vasodepression	8686
blockade	8673	HYDROCHLOROTHIAZIDE	(118)
ganglionic stimulants	8714	acetazolamide combination	8720
preganglionic nerve		antidiuretic effect	8720
stimulation	8672	diabetes insipidus	8720
8673		probenecid influence	8720
sympathetic ganglia	8672	<u>Gamma</u> -HYDROXYBUTYRATE, SODIUM	
8673		albino mice	(119) 8705
HEXAMETHONIUM-N-METHYL-C ¹⁴	(114)	behavioral studies	8705
anesthetized cats	8713	blood pressure	8705
autoradiograms	8713	CNS depressant	8705
blood pressure	8713	EEG	8705
distribution volume	8713	heart rate	8705
ganglion blockade	8713	lethal toxicity	8705
ganglion concentrations	8713	pentobarbital comparison	8705
intravenous administration	8713	5-HYDROXYTRYPTAMINE	(120)
nephrectomy	8713	albino rats	8667
nictitating membrane	8713	anesthetized cat	8714
pharmacological activity	8713	bioassay	8667
plasma concentration	8713	brain content	8667
pupillary light response	8713	8707	
renal clearance	8713	CNS depressants	8667
tissue distribution	8713	fluorimetric assay	8667
tissue/plasma ratios	8713	ganglionic blocking agents	8714
urinary excretion	8713	ganglionic receptors	8714

SUBJECT INDEX

1962

HYD-ISO

ganglionic stimulant action	8714	INTESTINAL MOTILITY	(125)
inferior mesenteric ganglion	8714	cat small intestine	8669
intraperitoneal		tetrahydrocannabinols	8669
administration	8667	INTESTINE, ISOLATED	(126)
morphine tolerant animals	8707	atropine effect	8676
nalorphine-induced abstinence	8707	dose-response curves	8670
HYPERGLYCEMIA	(121)	motility	8676
adrenalectomy	8711	muscle strips	8676
adrenergic blockade	8711	rabbit ileum strips	8670
2,2'-bipyridine induced	8711	reserpine pretreatment	8670
blood glucose	8711	retama	8676
dihydroergotamine		sympathomimetic amines	8670
pretreatment	8711	tone changes	8676
edathamil calcium disodium		INTESTINE, SMALL	(127)
pretreatment	8711	catecholamine content	8708
fasted rats	8711	morphine-tolerant animals	8708
ferrous iron pretreatment	8711	INULIN-H ³	(128)
pentobarbital-morphine		anesthetized rabbits	8703
pretreatment	8711	CSF-blood transport	8703
spinal transection	8711	intracisternal injection	8703
zinc pretreatment	8711	intraventricular injection	8703
HYPERTENSION, EXPERIMENTAL	(122)	urinary excretion	8703
atherogenic diet	8718	iodoacetate	(129)
body weight	8718	contraction rate	8719
male rats	8718	prolonged stimulation	8719
mecamylamine effect	8718	ryanodine pretreatment	8719
reserpine effect	8718	skeletal muscle relaxation	8719
serum cholesterol level	8718	stimulation frequency	8719
systolic pressure	8718	twitch contraction height	8719
HYPNOTICS	(123)	IPRONIAZID	(130)
action duration	8704	MAO inhibitor activity	8664
albino mice	8704	NQS effect	8664
chloral hydrate	8704	preincubation period	8664
depression stages	8704	ISOCARBOXAZID	(131)
intraperitoneal injection	8704	alkylhydrazid analogs	8664
intravenous injection	8704	BZH formation	8664
neurological state	8704	concentration effect	8664
trichloroethanol	8704	MAO inhibitor activity	8664
		NQS influence	8664
		preincubation period	8664
INOTROPISM	(124)	ISOPROPYLHYDRAZINE	(132)
aldosterone	8675	MAO inhibitor activity	8664
cat papillary muscle	8717	preincubation period	8664
catecholamine release	8717	ISOPROTERENOL	(133)
heart-lung preparation	8717	bronchomotor responses	8692
isolated cat auricles	8717	DCI pretreatment	8692
isolated heart muscle	8675	inhibitor activity	8670
ouabain	8675	isolated rabbit ileum	8670
N-oxide analogs	8717	perfusion pressure	8692
pH values	8675	pulmonary arterial pressure	8692
pyridine derivatives	8717	reserpine pretreatment	8670
SC-8109	8675		

SUBJECT INDEX

ISO-MER

VOL. 135

ventilation overflow	8692	LYSERGIC ACID DIETHYLAMIDE (140)	
		blocking action	8714
		ganglionic stimulants	8714
KIDNEY	(134)		
creatinine clearance	8681		
electrolyte excretion	8681	MANNITOL	(141)
meralluride	8681	CSF-blood transport	8703
mercurial diuretics	8681	intraventricular injection	8703
nondiuretic mercurials	8681	urinary excretion	8703
perfusion pressure	8681	MECAMYLAMINE	(142)
renal blood flow	8681	ACh responses	8672
urine flow	8681	DFP-induced postganglionic	
water excretion	8681	discharge	8672
		experimental atheromatosis	8718
		hypertensive rats	8718
LIPID-SOLUBILITY	(135)	hypocholesterolemic effect	8718
anesthetized rabbits	8703	hypotensive activity	8718
CSF-blood transport	8703	normotensive rats	8718
lipid-insoluble substances	8703	oral administration	8718
LIVER DAMAGE	(136)	postganglionic action	
acute ethanol intoxication	8699	potentials	8672
albino mice	8699	sympathetic ganglia	8672
chloroform induced	8699	MEPERIDINE	(143)
function tests	8699	brain 5-HT content	8667
histopathologic examination	8699	cerebral cortical slices	8700
LIVER FLUKE	(137)	cross-cellular adaptation	8700
adenosine-3',5'-phosphate		morphinized rats	8700
formation	8679	MEPROBAMATE TOLERANCE	(144)
aerobic glycolysis	8679	development mechanism	8695
anaerobic glycolysis	8679	male albino rats	8695
enzyme activity	8679	MEPROBAMATE-C ¹⁴	(145)
fasciola hepatica	8679	blood levels	8695
glucose utilization	8679	brain levels	8695
glycolytic enzyme systems	8679	daily administration	8695
hexosephosphate concentration	8679	excretion rate	8695
homogenate preparations	8679	fat levels	8695
intact parasites	8679	fecal excretion	8695
lactic acid production	8679	intraperitoneal injection	8695
phosphofructokinase activity	8679	male albino rats	8695
serotonin effect	8679	meprobamate-pretreated	
substrate effect	8679	animals	8695
LIVER FUNCTION	(138)	metabolic inactivation	8695
albino mice	8699	muscle levels	8695
BSP retention	8699	nontolerant animals	8695
chloroform pretreatment	8699	tolerance development	8695
ethanol pretreatment	8699	urinary excretion	8695
succinic dehydrogenase		urinary metabolite excretion	8695
activity <u>in vitro</u>	8699	whole body activity	8695
LOBELINE	(139)	MERCURIAL COMPOUNDS	(146)
anesthetized rats	8677	renal circulation	8681
antidiuretic activity	8677	renal perfusion pressure	8681
vasopressin release	8677		

SUBJECT INDEX

1962

MER-MOR

- | | | | |
|--|-------|---------------------------------------|-----------|
| urinary sodium concentration | 8681 | MONOAMINE OXIDASE | (155) |
| urine flow | 8681 | activity assay <u>in vitro</u> | 8665 |
| vasoconstrictor activity | 8681 | aerobic preincubation | 8664 |
| MERCURIALS, NONDIURETIC | (147) | anaerobic preincubation | 8664 |
| electrolyte excretion | 8681 | BAH-induced inhibition | 8664 |
| inhibitor activity | 8680 | p-dimethylaminobenzyl | |
| mercurial diuresis | 8680 | hydrazine inhibition | 8664 |
| perfused kidney | 8681 | heart | 8665 |
| water excretion | 8681 | iproniazid inhibition | 8664 |
| MERSALYL | (148) | ISH inhibition | 8664 |
| p-CMB reversal | 8680 | isocarboxazid inhibition | 8664 |
| diuretic response | 8680 | rat liver mitochondria | 8664 |
| mercuric chloride:glutathione | 8680 | sympathetic ganglia | 8665 |
| methyl mercury chloride | 8680 | tissue homogenates | 8665 |
| METABOLISM, DRUG | (149) | MONOAMINE OXIDASE INHIBITORS | |
| albino mice | 8704 | brain 5-HT content | (156)8667 |
| chloral hydrate | 8704 | brain norepinephrine content | 8706 |
| conjugate formation | 8693 | harmaline | 8667 |
| cotinine | 8709 | hydrazine derivatives | 8664 |
| desmethylcotinine excretion | 8709 | isocarboxazid | 8664 |
| H^3 -dichloroisoproterenol | 8693 | morphine-tolerant animals | 8708 |
| 3,4-dichloromandelic acid | | morphine-tolerant rats | 8706 |
| formation | 8693 | non-hydrazine derivatives | 8664 |
| enzymatic reduction | 8704 | NQS effect | 8664 |
| human subjects | 8709 | 1-phenyl-2-hydrazinopropane | |
| hydroxycotinine | 8709 | (JB 516) | 8706 |
| oxidative deamination | 8693 | 8708 | |
| <u>gamma</u> -(3-pyridyl)- <u>beta</u> -N-oxo- | | rat liver mitochondria | 8664 |
| methylbutyramide | 8709 | tissue catecholamines | 8708 |
| tissue distribution | 8693 | MORPHINE | (157) |
| trichloroethanol formation | 8704 | adrenal catecholamine content | 8706 |
| urinary metabolites | 8693 | albino rats | 8667 |
| 8709 | | 8678 | |
| METAGLYCODOL | (150) | blocking action | 8714 |
| amphetamine mortality | 8698 | body temperature | 8706 |
| antagonist activity | 8698 | brain <u>gamma</u> -aminobutyric acid | 8707 |
| hexobarbital sleeping time | 8698 | brain catecholamine content | 8706 |
| mouse strains | 8698 | brain 5-HT content | 8667 |
| METHADONE | (151) | 8707 | |
| cerebral cortical slices | 8700 | cardiac catecholamines | 8708 |
| cross-cellular adaptation | 8700 | cellular adaptation | 8678 |
| morphinized rats | 8700 | cerebral cortical slices | 8678 |
| METHAZOLAMIDE | (152) | 8700 | |
| brain 5-HT content | 8667 | chronic administration | 8706 |
| carbonic acid inhibitor | 8667 | 8707 8708 | |
| METHYL MERCURIC CHLORIDE | (153) | cross-cellular adaptation | 8700 |
| mercurial diuresis | 8680 | depression adapted rats | 8700 |
| nondiuretic mercurial | 8680 | excitatory abstinence | |
| METHYL-OCTYL-PYRAN (MOP) | (154) | syndrome | 8706 |
| chemical structure | 8669 | experimental animals | 8706 |
| pharmacological effects | 8669 | ganglionic stimulants | 8714 |

S-15

SUBJECT INDEX

MOR-NAL

VOL. 135

intestine catecholamines	8708	bronchioles	8692
JB-516 effect	8708	bronchomotor responses	8692
meperidine	8700	chicken urine-samples	8686
methadone	8700	compound 48/80 treated	
morphine-induced convulsions	8708	chickens	8686
nalorphine effect	8706	contraction response	8686
8708		dichloroisoproterenol	8692
nalorphine reversal	8678	guinea-pig ileum	8686
nalorphine-induced abstinence	8707	histamine treated chickens	8686
pentobarbital anesthesia	8706	intestinal strips	8686
sedation	8706	isolated rabbit aorta	8715
single doses	8707	"muscarinic" receptors	8671
8708		nictitating membrane	8671
splenic catecholamines	8708	8690	
tissue norepinephrine	8708	norepinephrine content	8690
tolerance effects	8706	pressor substance	
8707 8708		pretreatment	8715
withdrawal response	8678	pulmonary vasomotor responses	8692
MOUSE STRAINS	(158)	<u>alpha</u> -receptors	8692
aggregated animals	8698	<u>beta</u> -receptors	8692
amphetamine mortality	8698	serotonin desensitization	8686
anticonvulsant effects	8698	serotonin treated chickens	8686
drug antagonists	8698	sympathetic nerve stimulation	8692
drug susceptibility	8698	sympathomimetic	
hexobarbital sleeping time	8698	bronchodilators	8692
isolated animals	8698	tolazoline pretreatment	8692
mixed strains	8698	tripelennamine blocking	
mortality determinations	8698	action	8686
strain difference	8698	tryptamine treated chickens	8686
variable responses	8698	MYOCARDIAL CONTRACTILITY	(161)
MUSCLE, SKELETAL	(159)	intact rabbit heart	8685
acid-extract analysis	8719	isolated heart muscle	8685
ATP levels	8719	ouabain effect	8685
contraction rate	8719	pentobarbital-induced	
creatine phosphate levels	8719	depression	8685
frog sartorius	8719	post-stimulation potentiation	8685
<u>L-alpha</u> -GP levels	8719	rate-dependent mechanism	8685
IAA rigor	8719	NALORPHINE	(162)
iodoacetate effect	8719	antagonist:agonist ratio	8678
prolonged stimulation	8719	cerebral cortical cells	8678
relaxation mechanism	8719	cerebral cortical slices	8700
relaxation rate	8719	cross-cellular adaptation	8700
ryanodine effect	8719	KCl-stimulated cortical	
ryanodine rigor	8719	slices	8678
ryanodine-IAA effect	8719	morphine adaptation	8678
stimulation frequency	8719	morphinized rats	8700
twitch contraction height	8719	nalorphine-morphine	
MUSCLE, SMOOTH	(160)	combination	8678
acetylcholine response	8671	narcotics	8700
8715		reversing action	8678
atropine pretreatment	8692		

1,2-NAPHTHOQUINONE-4-SULFONATE		tyramine	8671
SODIUM (NQS) (163)		NOREPINEPHRINE (167)	
BZH-induced MAO inhibition		acetylcholine response	8715
<u>in vitro</u>	8664	binding sites	8690
isocarboxazid-induced MAO		bronchomotor responses	8692
inhibition <u>in vitro</u>	8664	DCI pretreatment	8692
NARCOTICS (164)		dose-response curves	8670
cellular adaptation	8678	8671	
cerebral cortical slices	8678	inhibitor activity	8670
8700		isolated aorta	8715
cross-cellular adaptation		isolated rabbit ileum	8670
<u>in vitro</u>	8700	membrane catecholamine	
morphine tolerance	8678	content	8690
morphinized rats	8700	nictitating membrane	8671
nalorphine reversal	8678	nictitating membrane	
NICOTINE (165)		sensitivity	8690
anesthetized rats	8677	phenoxybenzamine modification	8671
antidiuretic potency	8677	removal mechanism	8690
vasopressin release	8677	reserpine pretreatment	8670
NICTITATING MEMBRANE (166)		NUCLEIC ACID FRAGMENTS (168)	
acetylcholine action	8671	adenines	8712
anesthetized cats	8690	cardiac nerve stimulation	8712
8713		cytidines	8712
catecholamine content	8690	drug effects	8712
C6-Cl ⁴ ganglion concentration	8713	heart muscle extracts	8712
contractile responses	8690	hypoxanthine	8712
8713		inosines	8712
dose-response curves	8671	open-chest dogs	8712
epinephrine sensitivity	8690	uridines	8712
hexamethonium-Cl ⁴	8713	xanthine	8712
"muscarinic" receptors	8671		
norepinephrine	8671	OUABAIN (169)	
norepinephrine sensitivity	8690	frequency-force relationship	8685
phenoxybenzamine modification	8671	inotropic action	8675
postganglionic denervation	8690	isolated heart muscle	8675
preganglionic denervation	8690	8685	
preganglionic nerve		pH values	8675
stimulation	8671	post-stimulation potentiation	8685
8674		"therapeutic" effect	8685
preganglionic sympathetic		"toxic" effect	8685
stimulation	8713	OXYGEN CONSUMPTION (170)	
reserpine pretreatment	8671	albino rats	8678
8690		cerebral cortical slices	8678
spinal cats	8671	8700	
superior cervical ganglion	8674	cross-cellular adaptation	8700
superior cervical		KCl-stimulatory response	8678
ganglionectomy	8671	meperidine	8700
sympathetic nerve stimulation	8669	methadone	8700
TEA pretreatment	8674	morphine-induced cellular	
tetrahydrocannabinols	8669	adaptation	8678
tremorine effect	8674		

SUBJECT INDEX

OXY-PLA

VOL. 135

morphinized rats	8700	subcutaneous temperature	8694
nalorphine reversal	8678	"total" acetylcholine activity	8696
PAPILLARY MUSCLES (171)		PENTOBARBITAL HYPNOSIS (175)	
aldosterone	8675	albino mice	8699
antiarrhythmia agents	8684	chloroform pretreatment	8699
DCI pretreatment	8717	ethanol pretreatment	8699
epinephrine	8717	sleeping time	8699
inotropic effects	8675	PENTYLENETETRAZOL (176)	
8717		cardiac arrhythmias	8684
ouabain	8675	cardiac tissue	8684
N-oxide analogs	8717	concentration effect	8684
pentylenetetrazol	8684	convulsant threshold	8698
pyridine derivatives	8717	mouse susceptibility	8698
reserpine pretreatment	8717	parasympathetic blocking agents	8684
SC-8109	8675	phenobarbital antagonism	8698
SKF-6890A pretreatment	8717	strain difference	8698
PARASYMPATHETIC BLOCKING AGENTS		PHENOBARBITAL (177)	
N-ethyl-nortropine-benzhydryl-ether (172)	8684	amphetamine mortality	8698
pentylenetetrazol-induced arrhythmias	8684	antagonist activity	8698
PARASYMPATHETIC NERVOUS SYSTEM, GANGLION (173)		mouse strains	8698
blocking effect	8713	PHENOLSULFONPHTHALEIN (178)	
hexamethonium-C14 concentration	8713	CSF disappearance rate	8703
tremorine inhibitor activity	8674	intracisternal injection	8703
tremorine stimulant activity	8674	intraventricular injection	8703
PENTOBARBITAL (174)		plasma levels	8703
acute toxicity	8694	transport process	8703
anesthetized rats	8696	urinary excretion	8703
blood levels	8694	PIPERACETAZINE (179)	
brain concentration	8694	amphetamine mortality	8698
brain esters	8696	antagonist activity	8698
brain 5-HT content	8667	lethal effect	8698
brain-blood concentration ratio	8694	mouse susceptibility	8698
diffusion rate	8694	strain difference	8698
distribution volume	8694	PLASMA (180)	
environmental temperature	8694	catecholamine concentration	8716
gamma-hydroxybutyrate	8705	cyclopropane inhalation	8716
liver concentration	8694	H ³ -DCI concentration	8693
liver-blood concentration ratio	8694	disappearance rates	8693
male rats	8694	8713	
mortality rate	8694	epinephrine concentration	8716
oil-water distribution	8694	fluorescence development	8710
plasma protein binding	8694	fluorimetric determination	8710
rectal temperature	8694	hexamethonium-C14 concentration	8713
sleeping time	8705	human subjects	8710
		oral spironolactone administration	8710
		spironolactone metabolite levels	8710

SUBJECT INDEX

1962

PLA-RET

sulfuric acid-fluorogen	8710	RESERPINE	(188)
tissue/plasma ratios	8713	blood-brain barrier	8666
POLYMYXIN B	(181)	epinephrine uptake	8666
albino rats	8702	experimental atheromatosis	8718
drug antagonism	8702	guanethidine comparison	8688
gastric hemorrhage production	8702	hypertensive rats	8718
gastric ulcer formation	8702	hypcholesterolemic effect	8718
histamine liberation	8702	hypotensive activity	8718
intraperitoneal injection	8702	inhibitor activity	8666
pylorus-ligated rats	8702	isolated mammalian heart	8688
subcutaneous injection	8702	isolated rabbit ileum	8670
time-response curves	8702	normotensive rats	8718
POSTERIOR PITUITARY HORMONE		oral administration	8718
(VASOPRESSIN)	(182)	organ sensitivity	8670
coronary blood flow	8677	pretreatment effect	8670
coronary vasoconstriction	8677	special CNS areas	8666
ECG	8677	sympathomimetic amines	8670
isolated heart	8677	RESORCINOL ISOMERS	(189)
lobeline-induced release	8677	arterial pressure responses	8689
nicotine-induced release	8677	cardiac contraction force	8689
PROCAINE	(183)	cardiovascular system	8689
ACh responses	8672	open-chest dogs	8689
cervical sympathetic ganglion	8672	spinal cord action site	8689
DFP-induced postganglionic		sympathetic stimulatory	
discharge	8672	effect	8689
postganglionic action		RESPIRATION	(190)
potentials	8672	anesthetized cats	8669
PUPIL	(184)	carotid sinus denervation	8676
carbachol pretreatment	8674	hexamethonium blockade	8676
hexamethonium pretreatment	8674	rate changes	8669
phenoxybenzamine pretreatment	8674	respiratory paralysis	8669
tremorine-induced mydriasis	8674	retama stimulatory action	8676
PYRIDINES	(185)	tetrahydrocannabinols	8669
atropine pretreatment	8717	RETAMA	(191)
cardiac effects	8717	adrenalectomy	8676
catecholamine release	8717	adrenergic blocking agents	8676
dose-response curves	8717	anesthetized dogs	8676
methyl derivatives	8717	atropine pretreatment	8676
nicotine pretreatment	8717	B-TM-10 pretreatment	8676
N-oxide analogs	8717	cardiovascular actions	8676
PYRILAMINE	(186)	carotid sinus denervation	8676
polymyxin B-induced		hexamethonium blockade	8676
gastric hemorrhage	8702	hexamethonium pretreatment	8676
protective effect	8702	isolated intestine	8676
		isolated uterus	8676
		peripheral actions	8676
REFLEXES	(187)	phenoxybenzamine pretreatment	8676
flexion reflex	8669	respiration	8676
knee jerk	8669	smooth muscle	8676
linguomandibular reflex	8669	sympathectomy	8676
tetrahydrocannabinols	8669	vagotomy	8676

SUBJECT INDEX

RYA-SYM

VOL. 135

RYANODINE	(192)	SPLEEN	(198)
alpha-glycerokinase	8719	catecholamine content	8708
L-alpha-GP dehydrogenase	8719	morphine-tolerant animals	8708
iodoacetate effect	8719	STOMACH	(199)
skeletal muscle relaxation	8719	albino rats	8702
		atropine	8702
		gastric secretion	8702
SACCHARIDES-C ¹⁴	(193)	hemorrhagic lesions	8702
anesthetized rabbits	8703	histamine	8702
CSF disappearance rates	8703	histamine content	8702
intracisternal injection	8703	polymyxin B	8702
intravenous injection	8703	pylorus-ligated rats	8702
intraventricular injection	8703	serotonin content	8702
plasma levels	8703	STRYCHNINE	(200)
urinary excretion	8703	lethal effects	8698
SALIVARY SECRETION	(194)	mephenesin antagonism	8698
atropine blockade	8674	meprobamate antagonism	8698
chorda tympani section	8674	mouse susceptibility	8698
hexamethonium	8674	strain difference	8698
submaxillary gland	8674	SUCROSE	(201)
tetraethylammonium blockade	8674	CSF-blood transport	8703
tremorine-induced salivation	8674	intraventricular injection	8703
SEROTONIN	(195)	urinary excretion	8703
acetylcholine response	8715	SULFONAMIDES	(202)
anesthetized chickens	8686	antidiuretic activity	8720
aortic chains	8715	diabetes insipidus	8720
dose-response curves	8715	metabolic responses	8720
glycolytic enzyme activity	8679	saliuretic compounds	8720
histamine depleted animals	8686	structure action relationship	8720
histamine release	8686	urinary electrolyte excretion	8720
pressor response	8686	urine volume	8720
intact parasites	8679	water intake	8720
liver fluke homogenates	8679	SYMPATHETIC NERVOUS SYSTEM	(203)
vasodepressor response	8686	brain norepinephrine function	8706
SPINAL CORD	(196)	bronchomotor response	8692
action site	8689	cardiovascular reflexes	8668
acute transection	8689	cardiovascular stimulation	8689
resorcinol isomers	8689	central administration	8668
sympathetic circulatory		DCI pretreatment	8692
stimulation	8689	guanethidine effect	8668
SPIRONOLACTONE (ALDACTONE)	(197)	intravenous administration	8668
de-thioacetylated derivative		morphine-tolerant animals	8706
(SC-9376)	8710	resorcinol isomers	8689
fluorimetric determination	8710	spinal cord action site	8689
human subjects	8710	splanchnic nerve activity	8668
oral administration	8710	thoracic postganglionic	
plasma metabolite levels	8710	stimulation	8692
plasma sulfuric acid-		SYMPATHETIC NERVOUS SYSTEM,	
fluorogen	8710	GANGLION	(204)
SC-9376 structural		acetylcholine effect	8672
relationship	8710	anesthetized cats	8672
		8673	

atropine effect	8672	DCI reversing action	8692
bioassay	8665	pulmonary arterial injection	8692
blocking effect	8713	sympathetic nerve stimulation	8692
cell group responses	8673	ventilation overflow	8692
chronic denervation	8672		
DFP effect	8673	TEMPERATURE, ENVIRONMENTAL (208)	
DFP-induced postganglionic discharge	8672	barbital distribution	8694
differential blockade	8673	barbital toxicity	8694
epinephrine content	8690	male rats	8694
external carotid nerve	8673	pentobarbital distribution	8694
functional heterogeneity	8673	pentobarbital toxicity	8694
ganglionic blocking agents	8672	TEMPERATURE, RECTAL (209)	
8673		barbital distribution	8694
ganglionic stimulants	8673	barbital toxicity	8694
hexamethonium-Cl ⁴		male rats	8694
concentration	8713	pentobarbital distribution	8694
intra-arterial injections	8672	pentobarbital toxicity	8694
8673		TETRAETHYLAMMONIUM (210)	
MAO activity	8665	ACh responses	8672
norepinephrine content	8690	chronic denervation	8672
postganglionic action		DFP-induced postganglionic discharge	8672
potentials	8673	differential ganglionic blockade	8673
preganglionic nerve stimulation	8672	dose effect	8673
8673		postganglionic action potentials	8673
preganglionic section	8690	preganglionic nerve stimulation	8672
procaine effect	8672	repetitive preganglionic stimulation	8673
reserpine pretreatment	8690	sympathetic ganglia	8672
retama stimulatory effect	8676	8673	
superior cervical ganglion	8672	TETRAHYDROCANNABINOLS (211)	
8673 8690		action site	8669
through fibers	8673	amphetamine-induced activity	8669
thyroid nerve	8673	anesthetized cats	8669
<u>d</u> -tubocurarine effect	8672	atropine pretreatment	8669
SYMPATHETICO-ADRENAL SYSTEM(205)		blood pressure	8669
anesthetized dogs	8716	carotid sinus denervation	8669
cyclopropane responses	8716	decerebrate cats	8669
nictitating membrane	8716	dibenamine pretreatment	8669
pupil diameter	8716	intestinal motility	8669
SYMPATHOMIMETIC AMINES (206)		nictitating membrane	8669
dose-response curves	8670	pharmacological effects	8669
inhibitor activity	8670	piperoxan pretreatment	8669
isolated rabbit ileum	8670	reflexes	8669
organ sensitivity	8670	respiration	8669
reserpine pretreatment	8670	spinal section	8669
SYMPATHOMIMETIC BRONCHODILATORS		toxicity	8669
anesthetized dogs (207)	8692	vagotomy	8669
arterial perfusion pressure	8692		
bronchomotor responses	8692		

SUBJECT INDEX

TRA-VAS

VOL. 135

TRANSMISSION, GANGLIONIC (212)		histamine release	8686
anesthetized cats	8674	pressor response	8686
DMPP response	8674	vasodepressor response	8686
inferior mesenteric ganglion	8674	<u>d</u> -TUBOCURARINE (217)	
postganglionic discharge	8674	acetylcholine responses	8672
superior cervical ganglion	8674	DFP-induced postganglionic	
tremorine	8674	discharge	8672
TRANSMISSION, SYMPATHETIC		intra-arterial injection	8672
GANGLIONIC (213)		preganglionic stimulation	8672
acetylcholine effect	8672	sympathetic ganglia	8672
DFP-induced postganglionic		TYRAMINE (218)	
discharge	8672	action mechanism	8670
ganglionic blocking agents	8672	dose-response curves	8671
intra-arterial injections	8672	inhibitor activity	8670
postganglionic action		isolated rabbit ileum	8670
potentials	8672	nictitating membrane	8671
preganglionic nerve		phenoxybenzamine modification	8671
stimulation	8672	reserpine pretreatment	8670
presynaptic terminals	8672		
TREMORINE (214)		UTERUS (219)	
action sites	8674	isolated guinea-pig uterus	8676
anesthetized dogs	8674	retama	8676
autonomic effects	8674		
biphasic effect	8674	VASOCONSTRICTORS (220)	
cardiovascular system	8674	acetylcholine activity	8715
cholinesterase inhibition	8674	isolated aorta	8715
hypothermic response	8674	VASODEPRESSION (221)	
peripheral ganglionic		anesthetized chickens	8686
activity	8674	histamine mediated mechanism	8686
urinary bladder	8674	serotonin response	8686
TRICHLOROETHANOL (215)		tryptamine response	8686
albino mice	8704	VASODILATORS (222)	
brain tissue concentration	8704	acetylcholine activity	8715
chloral hydrate comparison	8704	isolated aorta	8715
chloral hydrate metabolite	8704	VASOMOTOR SYSTEM (223)	
hypnotic activity	8704	central inhibition	8668
TRYPTAMINE (216)		guanethidine effect	8668
anesthetized chickens	8686		
histamine depleted animals	8686		

AUTHOR INDEX

1962

VOL. 135

Abbott B C	8719	Gochman N	8710	Paasonen M K	8688
Allmark M G	8677	Grewal R S	8677	Page I H	8668
Alper M H	8688	Groisser V W	8701	Penna M	8692
Anderson E G	8667	Gyermek L	8714	Phillips B M	8695
Ara R	8696			Plaa G L	8699
Aramendia P	8687			Price H L	8697
Aviado D M	8687	Haugaard N	8691	8716	
8692		Hess M E	8691	Prockop L D	8703
		Hilton J G	8676		
		Hosein E A	8696		
Ballard B E	8682			Robb J S	8712
Bindler E	8714			Rossi G V	8718
Bonnycastle D D	8667	Jelliffe R W	8715		
Bonnycastle M F	8667	Jenden D J	8719		
Bowman E R	8709			Schanke L S	8703
Boyd E S	8669			Schmidt J L	8670
Brodie B B	8703	Kaji H K	8707	Schneider J A	8705
Brodie D A	8702	Kaneko Y	8668	Schoepke H G	8717
Bunag R D	8686	Kenny A D	8711	Schwartz M A	8664
		Kerley T L	8698	Seraydarian M W	8719
		Kirpekar S M	8690	Setnikar I	8694
Cafruny E J	8681	Klingman G I	8706	Shanfeld J	8691
Castro de la Mata R	8687 8692	8707 8708		Shideman F E	8717
		Krayer O	8688	Sjoerdsma A	8665
Cervoni P	8690	Kutob S D	8699	Smith C M	8674
Cooper J R	8704			Smith T H F	8718
Covino B G	8684				
Crawford J D	8720	Levine R J	8665		
		Linde H W	8716	Takemori A E	8678
		Lovenberg W	8665	8700	
Dagirmanjian R	8669	Lu F C	8677	Tanz R D	8675
Deutsch S	8716			Temelcou O	8694
Drakontides A B	8705			Terry M L	8720
Dunn M J	8676	McCubbin J W	8668	Titus E	8666
		McIsaac R J	8713	Trendelenburg U	8671
Easton N R	8683	Mackay F J	8704	Tuttle R S	8685
		McKennis H Jr	8709		
		McMahon R E	8683	Vargas R	8681
Farah A E	8680	Mansour T E	8679	Volle R L	8672
8685		Martinez		8673	
Fleming W W	8670	L de Letona J	8687		
Floch M H	8701	Mayer S E	8693		
Friedman A H	8674	Maynert E W	8706		
Frost L	8720	8707 8708		Walaszek E J	8686
Funderburk W H	8705	Miller T B	8680	Walton R P	8689
Furchgott R F	8690	Miya T S	8695	Weaver L C	8698
		Moreno O M	8702	Welsh M	8720
		Morey E R	8711	Widdicombe J	8697
Gantt C L	8710	Murray A W	8666	Wilson C W M	8666
Gatgounis J	8689				
Gillen W	8684	Nelson E	8682	Yim G K W	8695

to Subscribers and Readers

Because of the comprehensive nature of the Journal index, the following explanatory comment, with special reference to subject analysis, seems appropriate at this time.

Subject Content: This is available to the reader by simple, coordinate search of the Subject Index. Coincident display of pertinent headings and subheadings, arranged alphabetically, assures the searcher that significant information will not be missed. The information thus acquired may be divided into three categories:

First: The Number of Articles Cited on Each Subject.

Rapid survey of the entry numbers listed opposite the subheadings will indicate the scope and variety of topic coverage. The subheadings describe the subject content in unit terms, with separate access for each idea.

For the convenience of direct page reference, AUXILIARY INDEX-PART I presents a table of Index to Pages.

Second: The Number of Subjects Covered in Each Article.

The Subject Index admits topic headings according to the relative importance of competing information within each article. By the liberal use of these selected headings, numbered serially in parenthesis, a convenient system of complete cross-reference is provided for the reader.

For the purpose of cross-reference, AUXILIARY INDEX-PART II is recommended.

It presents a table of index to Subject Headings, in which the heading numbers appear below the appropriate underscored entry numbers. The corresponding headings may be quickly located by reference to the parenthetic heading numbers in the subject index.

Third: The Associations of Ideas Related to the Subject of Search.

Ready comparison of ideas described under one heading with those listed under the alternative headings will often lead to a fund of relevant facts. In this manner, tracing ideas through the total system should open the way to useful material that is beyond the limits of restricted fields of inquiry.

Auxiliary Index-Part I

Index to Pages

VOLUME 135, 1962

JANUARY		FEBRUARY		MARCH	
<u>Entry</u>	<u>Page</u>	<u>Entry</u>	<u>Page</u>	<u>Entry</u>	<u>Page</u>
8664	1	8684	136	8703	266
8665	7	8685	142	8704	271
8666	11	8686	151	8705	275
8667	17	8687	156	8706	285
8668	21	8688	164	8707	296
8669	25	8689	174	8708	300
8670	34	8690	180	8709	306
8671	39	8691	191	8710	312
8672	45	8692	197	8711	317
8673	54	8693	204	8712	323
8674	62	8694	213	8713	335
8675	71	8695	223	8714	344
8676	79	8696	230	8715	349
8677	84	8697	233	8716	354
8678	89	8698	240	8717	358
8679	94	8699	245	8718	367
8680	102	8700	252	8719	374
8681	112	8701	256	8720	382
8682	120	8702	259		
8683	128				

<u>8664</u>	<u>8669</u>	<u>8673</u>	<u>8678</u>	<u>8685</u>	<u>8691</u>	<u>8698</u>	<u>8703</u>	<u>8709</u>	<u>8715</u>
30	36	204	39	4	89	177	51	66	21
130	50	210	49	44	108	179	70	149	91
131	78		157	64		200	128		160
132	115	<u>8674</u>	162	75	<u>8692</u>		135	<u>8710</u>	167
155	125	34	164	109	7	<u>8699</u>	141	180	195
156	154	36	170	161	73	9	178	197	220
163	166	62		169	91	54	193		222
	187	81	<u>8679</u>		133	89	201	<u>8711</u>	
<u>8665</u>	190	108	<u>89</u>	<u>8686</u>	160	93		6	<u>8716</u>
32	211	110	98	36	167	136	<u>8704</u>	33	36
89		166	102	116	203	138	39	37	45
105	<u>8670</u>	173	137	117	207	175	53	50	48
155	90	184	195	160			123	52	67
204	91	194		195	<u>8693</u>	<u>8700</u>	149	76	86
	126	212	<u>8680</u>	216	39	<u>39</u>	215	121	110
<u>8666</u>	133	214	55	221	74	49			180
39	167		56		149	143	<u>8705</u>	<u>8712</u>	205
50	188	<u>8675</u>	82	<u>8687</u>	180	151	39	105	
92	206	8	96	22		157	50	168	<u>8717</u>
188	218	10	147	40	<u>8694</u>	162	87		48
		108	148	79	<u>26</u>	164	115	<u>8713</u>	105
<u>8667</u>	<u>8671</u>	109	153	100	174	170	119	36	107
27	3	124			208		174	39	124
32	63	169	<u>8681</u>	<u>8688</u>	209	<u>8701</u>		99	171
39	160	171	55	103		29	<u>8706</u>	110	185
43	166		84	108	<u>8695</u>	35	5	114	<u>8718</u>
50	167	<u>8676</u>	134	110	<u>144</u>	89	38	166	20
53	218	36	146	188	145	112	39	173	36
80		108	147				48	180	61
95	<u>8672</u>	126		<u>8689</u>	<u>8696</u>	<u>8702</u>	156	204	122
104	3	190	<u>8682</u>	36	3	16	157		142
120	23	191	1	45	15	17	203	<u>8714</u>	188
143	77	204	85	105	39	19		23	
152	99	219		189	94	58	<u>8707</u>	24	<u>8719</u>
156	113		<u>8683</u>	196	174	60	11	31	129
157	142	<u>8677</u>	<u>42</u>	203		68	39	41	159
174	183	36	69		<u>8697</u>	72	120	63	192
	204	65	89	<u>8690</u>	<u>36</u>	91	157	72	<u>8720</u>
<u>8668</u>	210	83		48	46	101		79	2
36	213	86	<u>8684</u>	160	47	111		99	18
50	217	108	97	166	67	116	<u>8708</u>	100	28
103		139	106	167		117	48	113	57
203	<u>8673</u>	165	108	204	<u>8698</u>	181	105	120	59
223	3	182	109		13	186	127	140	71
	99		171	<u>8691</u>	150	199	156	157	88
<u>8669</u>	100	<u>8678</u>	172	25	158	<u>8703</u>	157	<u>8715</u>	118
12	113	14	176	45	176	<u>35</u>	198	3	202

NOTICE

to Subscribers and Readers

Attention is directed to the current method (ACC) of using entry numbers opposite the unit terms and names comprising the Subject and Author sections of the Journal Index. These entry numbers coincide with the appropriate accession numbers listed serially at the left of the titles in the Register of Articles. Their purpose is to condense and unify the three parts of the index, and to expedite its use.

For a brief guide to the use of the current index please consult pages AI-1, and AI-2. Objectives and method are discussed under Notice to Readers and Subscribers.

For direct page reference, an Index to Pages by entry numbers is tabulated on page AI-1.

For cross-reference of subject matter, an index to Subject Headings by entry numbers is presented on page AI-2.

The possibility has been considered that additional copies of the index, bound separately, might be of value to libraries and to other subscribers and readers for use in reference work. Such a separate distribution would be justified only if the sale of a significant number of copies could be assured. It is suggested that anyone interested in such separate indexes write a letter to the Publisher who can then determine the feasibility of separate distribution.